$SERA

Lindgardt Zhenya sold $43K of SERA

Lindgardt Zhenya (Chief Executive Officer) sold 20,755 shares of SERA PROGNOSTICS, INC. (SERA) at $2.08 on 2026-06-09.

Original reporting
SEC EDGAR · Lindgardt Zhenya
Published Jun 10, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
medium confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

An officer/director open-market sale can modestly affect retail sentiment, but without any accompanying corporate disclosure it typically has limited trading impact.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is unlikely to be a standalone catalyst.

03

What to watch

The article doesn’t state whether other insiders/large holders are buying, nor does it provide context for the sale (e.g., tax event, planned diversification).

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10; transaction dated 2026-06-09

Background

The article is an SEC Form 4 insider transaction filing for SERA PROGNOSTICS, INC.

Company-level read

Ticker impact

$SERANeutralMedium confidence
Context

SERA CEO Lindgardt Zhenya filed an open-market sale of 20,755 shares at $2.0800 on 2026-06-09 (Form 4).

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted and short-lived.

Evidence & confidence

Form 4 insider sales are common and the article provides no accompanying corporate event (no guidance, deal, or enforcement action). The sale is also not stated as part of a 10b5-1 plan, but the disclosure alone still lacks a direct business impact.

Market effects

No sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations.

Key entities

  • SERA PROGNOSTICS, INC.

    Company whose shares were sold by its CEO via an open-market transaction disclosed on Form 4.

  • Lindgardt Zhenya

    CEO and officer/director who sold 20,755 shares at $2.0800 on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t